Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
February 2020
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
-
Collaboration is strengthening care for chronic illness in Ethiopia
Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwideBeovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA reviewFDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 …
-
StatementAVXS-101 Managed Access Program
-
Featured NewsWorld Cancer Day 2020
Novartis is supporting World Cancer Day by reimagining cancer in the workplace through a dedicated global program.
-
Reimagining cancer in the workplace
Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).
-
In The NewsNovartis CEO Vasant Narasimhan on building trust with societyVas Narasimhan, CEO of Novartis, and CNBC’s Meg Tirrell joins “Closing Bell” in an exclusive interview at the JPMorgan Healthcare Conference.
-
In The NewsNovartis Pharmaceuticals head on chief, Marie-France Tschudin on rethinking the drug-launch formulaTschudin talks with FiercePharma at the J.P. Morgan Healthcare Conference.about a “value-based approach” to drug launches.
January 2020
-
Key ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicinesSuccessful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements…
-
Media ReleaseNovartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitisNew Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1 Label update provides clinicians with…
-
Featured NewsNovartis 2019 Financial Results
Novartis announces the company’s fourth quarter and 2019 full year financial results.
Pagination
- ‹ Previous page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- …
- 152
- › Next page